971-34-6

Basic information

• Product Name: N-[1-(benzyl)-4-piperidyl]benzamide
• Synonyms: N-[1-(benzyl)-4-piperidyl]benzamide;N-(1-Benzyl-4-piperidinyl)benzamide;N-(1-Benzylpiperidin-4-yl)benzamide;N-(1-Benzyl-4-piperidinyl)benzaMide (IndoraMin IMpurity);1-Benzyl-4-(phenylcarboxamido)piperidine
• CAS NO: 971-34-6
• Molecular Formula: C₁₉H₂₂N₂O
• Molecular Weight: 294.39078
• EINECS: 213-538-8
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Amines, Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 971-34-6.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 483.9°Cat760mmHg
• Flash Point: 246.5°C
• Appearance: /
• Density: 1.14g/cm³
• Vapor Pressure: 1.61E-09mmHg at 25°C
• Refractive Index: 1.61
• CAS DataBase Reference: N-[1-(benzyl)-4-piperidyl]benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[1-(benzyl)-4-piperidyl]benzamide(971-34-6)
• EPA Substance Registry System: N-[1-(benzyl)-4-piperidyl]benzamide(971-34-6)

Safety Data

• Hazardous Substances Data: 971-34-6(Hazardous Substances Data)

Usage

Uses

N-[1-(benzyl)-4-piperidyl]benzamide is an Indoramin impurity and can be used in the preparation of piperidinyl heterocycles as hD4 ligands.

InChI:InChI=1/C19H22N2O/c22-19(17-9-5-2-6-10-17)20-18-11-13-21(14-12-18)15-16-7-3-1-4-8-16/h1-10,18H,11-15H2,(H,20,22)

Upstream product

• 98-88-4 benzoyl chloride 
• 1315494-51-9 N-(3-fluoropyridin-4-yl)benzamide 
• 2247-88-3 3-fluoro-pyridin-4-ylamine 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 959-22-8 p-nitrophenylbenzoate 
• 4783-65-7 N-benzyl-2-piperidinone 
• 65-85-0 benzoic acid 

Downstream Products

• 1044-79-7 N-(1-benzylpiperidin-4-yl)-4-chlorobenzamide 
• 974-12-9 N-(1-benzyl-piperidin-4-yl)-4-methyl-benzamide 
• 577778-27-9 1-Acetyl-4-benzamidopiperidin 
• 33953-37-6 N-(piperidin-4-yl)benzamide 

Relevant articles and documents

Synthesis of a CGRP Receptor Antagonist via an Asymmetric Synthesis of 3-Fluoro-4-aminopiperidine

A practical and efficient enantioselective synthesis of the calcitonin gene-related peptide receptor antagonist 1 has been developed. The key structural component of the active pharmaceutical ingredient is a syn-1,2-amino-fluoropiperidine 4. Two approaches were developed to synthesize this important pharmacophore. Initially, Ru-catalyzed asymmetric hydrogenation of fluoride-substituted enamide 8 enabled the synthesis of sufficient quantities of compound 1 to support early preclinical studies. Subsequently, a novel, cost-effective route to this intermediate was developed utilizing a dynamic kinetic asymmetric transamination of ketone 9. This synthesis also features a robust Ullmann coupling to install a bis-aryl ether using a soluble Cu(I) catalyst. Finally, an enzymatic desymmetrization of meso-diester 7 was exploited for the construction of the γ-lactam moiety in 1.

Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer’s disease

In a continuing effort to develop multitargeted compounds as potential treatment agents against Alzheimer's disease (AD), a series of donepezil-like compounds were designed, synthesized and evaluated. In vitro studies showed that most of the designed compounds displayed potent inhibitory activities toward AChE, BuChE, MAO-B and MAO-A. Among them, w18 was a promising agent with balanced activities, which exhibited a moderate cholinesterase inhibition (IC50, 0.220 μM for eeAChE; 1.23 μM for eqBuChE; 0.454 μM for hAChE) and an acceptable inhibitory activity against monoamine oxidases (IC50, 3.14 μM for MAO-B; 13.4 μM for MAO-A). Moreover, w18 could also be a metal-chelator, and able to cross the blood–brain barrier with low cell toxicity on PC12 cells. Taken together, these results suggested that w18 might be a promising multitargeted compound for AD treatment.

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Areceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Areceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.